No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease
Abstract Background Non-alcoholic fatty liver disease is a common health problem associated with increased liver and vascular specific complications . Aim The purpose of this study was to assess and compare the effect of fenofibrate alone or in combination with pentoxifylline on the measured biochemical parameters , inflammatory pathway and liver stiffness in patients with non-alcoholic fatty liver disease . Methods The study design was r and omized controlled trial . From July 2013 to June 2014 , we recruited 90 non-alcoholic fatty liver patients from the Internal Medicine Department at Tanta University Hospital , Egypt . They were classified r and omly into two groups to receive fenofibrate 300 mg daily or fenofibrate 300 mg daily plus pentoxifylline 1200 mg/day in three divided doses for 24 weeks . Fasting blood sample was obtained before and 24 weeks after treatment for biochemical analysis of liver and lipid panels , tumor necrosis factor-alpha , hyaluronic acid , transforming growth factor beta 1 , fasting plasma insulin and fasting glucose . Liver stiffness measurement was carried out using fibro-scan . Data were statistically analyzed by paired and unpaired Student ’s t test . Results The data obtained suggests that adding pentoxifylline to fenofibrate does not provide a beneficial effect on lipid panel , but has a beneficial effect on indirect biochemical markers of hepatic fibrosis , a direct marker linked to matrix deposition ( hyaluronic acid ) , a cytokine/growth factor linked to liver fibrosis ( transforming growth factor beta 1 ) , the inflammatory pathway , insulin resistance and liver stiffness as compared to fenofibrate alone . Conclusion The combination pentoxifylline plus fenofibrate may represent a new therapeutic strategy for non-alcoholic fatty liver disease as it result ed in more beneficial effects on direct and indirect markers of liver fibrosis , liver stiffness , insulin resistance and inflammatory pathway implicated in NAFLD
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .